查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1427944

2024 年卵巢癌诊断全球市场报告

Ovarian Cancer Diagnostics Global Market Report 2024
出版日期: 按订单生产 | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10个工作天内

价格
简介目录

卵巢癌诊断的市场规模预计在未来几年将显着成长。预计到 2028 年将以 6.7% 的复合年增长率 (CAGR) 增长至 36.5 亿美元。延长的预测期与专注于早期检测、增加卵巢癌发病率、人工智慧 (AI) 整合、个人化医疗方法、新型生物标记的出现以及基因组和蛋白质组分析的采用有关。预测期内预计的主要趋势包括利用生物感测器技术进行早期检测、数位病理学的整合、诊断成像模式的创新、成像技术的增强以及病理技术的进步。

卵巢癌盛行率的预期增加预计将在可预见的未来推动卵巢癌诊断市场的成长。卵巢癌的特征是在女性生殖功能所必需的卵巢中发生恶性，并且由于平均寿命、生育延迟和生活方式改变等因素而迅速增加。这一转变凸显了卵巢癌诊断的重要性，它在早期发现和介入中发挥关键作用。早期诊断有助于及时治疗，进而改善患者的治疗效果。例如，根据加拿大非营利组织世界卵巢癌联盟的资料，2020 年全球有 313,959 名女性被诊断出罹患卵巢癌。预测显示，2040年，病例数将增加42%，达到445,721例，相应增加51%。死于卵巢癌的女性人数达313,617人。因此，卵巢癌盛行率的增加是推动卵巢癌诊断市场的关键因素。

妇科癌症的流行预计也将显着促进卵巢癌诊断市场的成长。妇科癌症包括源自女性生殖道的癌症，卵巢癌的诊断剂在降低其盛行率方面发挥重要作用。这些药物有助于妇科癌症的治疗和管理，透过不同的治疗方法预防復发并改善患者的预后。世界卵巢癌联盟的统计数据进一步强调了这一影响，预计卵巢癌病例数将从 2020 年的 313,959 例增加到 2040 年的 445,721 例，增加 42%。同期女性人数预计将增加 51%。卵巢癌死亡人数达 313,617 人。因此，妇科癌症的显着盛行率已成为卵巢癌诊断市场成长的驱动力。

目录

第一章执行摘要

第二章 市场特点

第三章 市场趋势与策略

第四章宏观经济情景

  • 高通膨对市场的影响
  • 乌克兰与俄罗斯战争对市场的影响
  • COVID-19 对市场的影响

第五章世界市场规模与成长

  • 全球市场驱动因素与限制因素
    • 市场驱动因素
    • 市场限制因素
  • 2018-2023 年全球市场规模表现与成长
  • 全球市场规模预测与成长，2023-2028、2033

第六章市场区隔

  • 全球卵巢癌诊断市场，依产品类型、表现及预测细分，2018-2023、2023-2028、2033
  • 装置
  • 套件
  • 试剂
  • 全球卵巢癌诊断市场，依诊断类型、实际及预测细分，2018-2023、2023-2028、2033
  • 切片检查
  • 验血
  • 影像
  • 其他诊断类型
  • 全球卵巢癌诊断市场，按癌症类型细分、实际和预测，2018-2023、2023-2028、2033
  • 上皮性肿瘤
  • 生殖细胞肿瘤
  • 间质细胞瘤
  • 其他癌症类型
  • 全球卵巢癌诊断市场，按最终用户细分，实际和预测，2018-2023、2023-2028、2033
  • 癌症诊断中心
  • 医院实验室
  • 研究机构

第 7 章 区域与国家分析

  • 全球卵巢癌诊断市场，按地区、绩效及预测，2018-2023、2023-2028、2033
  • 全球卵巢诊断市场，依国家、绩效及预测，2018-2023、2023-2028、2033

第八章亚太市场

第九章 中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第14章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章 义大利市场

第20章 西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章加拿大市场

第26章 南美洲市场

第27章 巴西市场

第28章 中东市场

第29章 非洲市场

第三十章 竞争形势及公司概况

  • 卵巢癌诊断市场竞争形势
  • 卵巢癌诊断市场的公司概况
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • AstraZeneca plc
    • Abbott Laboratories
    • GlaxoSmithKline plc

第31章 其他大型创新公司

  • Eli Lilly and Company
  • GE HealthCare Technologies Inc.
  • Quest Diagnostics Incorporated
  • Agilent Technologies Inc.
  • Hologic Inc.
  • Illumina Inc.
  • PerkinElmer Inc.
  • Sysmex Corporation
  • Bio-rad Laboratories Inc.
  • Qiagen NV
  • Natera Inc.
  • The American Cancer Society
  • Myriad Genetics Inc.
  • ArcherDX Inc.
  • Invitae Corporation

第32章竞争基准化分析

第 33 章. 竞争对手仪表板

第三十四章 重大併购

第35章 未来前景与可能性分析

第36章附录

简介目录
Product Code: r13788

Ovarian cancer diagnostics encompass a range of methods and procedures aimed at detecting and diagnosing ovarian cancer. This involves the evaluation of symptoms, physical examinations, and the application of various diagnostic tests. Ovarian cancer, a malignancy affecting the ovaries within the female reproductive system, necessitates accurate diagnostic approaches for timely and effective intervention.

The primary categories of ovarian cancer diagnostic products comprise instruments, kits, and reagents. Instruments play a pivotal role in medical diagnostics, encompassing imaging devices such as ultrasound and MRI, blood tests utilizing markers such as CA-125 and HE4, as well as tissue sampling techniques including biopsy and laparoscopy. Various diagnostic methods, such as biopsy, blood tests, imaging, and others, are deployed to identify specific types of ovarian cancer, including epithelial tumors, germ cell tumors, stromal cell tumors, among others. These diagnostic tools find application across diverse end-users, including cancer diagnostic centers, hospital laboratories, and research institutes. The comprehensive array of diagnostic techniques contributes to accurate and targeted identification of ovarian cancer subtypes, facilitating tailored treatment approaches.

The ovarian cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides ovarian cancer diagnostics market statistics, including ovarian cancer diagnostics industry global market size, regional shares, competitors with a ovarian cancer diagnostics market share, detailed ovarian cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the ovarian cancer diagnostics industry. This ovarian cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ovarian cancer diagnostics market size has grown strongly in recent years. It will grow from $2.62 billion in 2023 to $2.82 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The expansion observed in the historical timeframe can be ascribed to advancements in biomarker exploration and validation, increased adoption of transvaginal ultrasound, heightened awareness of BRCA gene mutations, intensified research on tumor markers, and the implementation of screening programs and guidelines.

The ovarian cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $3.65 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The anticipated expansion in the forecasted period is linked to initiatives focused on early detection, a rising incidence of ovarian cancer, the integration of artificial intelligence (AI), personalized medicine approaches, the emergence of novel biomarkers, and the adoption of genomic and proteomic profiling. Key trends expected in the forecast period encompass the utilization of biosensor technologies for early detection, integration of digital pathology, innovations in imaging modalities, enhancements in imaging technologies, and progress in pathology techniques.

The anticipated increase in the prevalence of ovarian cancer is expected to drive the growth of the ovarian cancer diagnostics market in the foreseeable future. Ovarian cancer, characterized by the development of malignant tumors in the ovaries, essential for female reproductive functions, has witnessed a surge due to factors such as prolonged life expectancy, delayed childbearing, and shifts in lifestyle. This transformation underscores the importance of ovarian cancer diagnostics, which play a pivotal role in early detection and intervention. Early diagnosis facilitates timely treatment, leading to improved outcomes for patients. For example, data from the World Ovarian Cancer Coalition, a Canada-based non-profit organization, revealed that ovarian cancer affected 313,959 women globally in 2020. The projections indicate a 42% increase to 445,721 cases by 2040, with a corresponding 51% rise in the number of women succumbing to ovarian cancer, reaching 313,617. Hence, the growing prevalence of ovarian cancer is a key factor propelling the ovarian cancer diagnostics market.

The prevalence of gynecological cancer is also poised to contribute significantly to the growth of the ovarian cancer diagnostics market. Gynecologic cancer encompasses cancers originating in a woman's reproductive organs, and ovarian cancer diagnosis drugs play a crucial role in reducing its prevalence. These drugs contribute to the treatment and management of gynecological cancer, preventing recurrence and enhancing patient outcomes through diverse therapeutic approaches. The statistics from the World Ovarian Cancer Coalition further emphasize the impact, projecting a 42% increase in ovarian cancer cases from 313,959 in 2020 to 445,721 by 2040. Over the same period, there is anticipated to be a 51% rise in the number of women succumbing to ovarian cancer, reaching 313,617. Consequently, the substantial prevalence of gynecological cancer emerges as a driving force behind the growth of the ovarian cancer diagnostics market.

The ovarian cancer diagnostics market is witnessing a notable trend with the increasing adoption of advanced diagnostic technology. Companies in this market are actively incorporating advanced diagnostic technologies as a strategic move to maintain their competitive positions. An illustrative example is Hoffmann-La Roche AG, a pharmaceutical and healthcare company based in Switzerland. In November 2022, the company secured FDA approval for the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This groundbreaking immunohistochemistry (IHC)-based companion diagnostic test kit identifies ovarian cancer patients eligible for the prescription medication ELAHERE. The approval signifies a significant advancement in diagnostic capabilities, providing critical insights and detailed clinical information for improved disease management and patient outcomes.

Major players in the ovarian cancer diagnostics market are actively engaging in partnerships to foster product development and fortify their market positions. Collaborative efforts in this sector contribute to enhanced research, development, and commercialization by leveraging the combined expertise, resources, and networks of multiple entities. For instance, in August 2023, ImmunoGen Inc., a US-based biotechnology company, joined forces with Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company. This partnership focuses on the development and commercialization of ELAHERE (mirvetuximab soravtansine-gynx) in Japan. ImmunoGen stands to benefit from upfront and milestone payments, along with double-digit royalties, while Takeda gains exclusive rights to develop and commercialize ELAHERE in Japan. This collaboration addresses an unmet need for individuals with platinum-resistant ovarian cancer, showcasing a shared commitment to advancing cancer treatment options on a global scale.

In September 2022, GENinCode PLC, a biotechnology company based in the UK specializing in genetic testing for assessing the risk of cardiovascular diseases, successfully completed the acquisition of Abcodia for a sum of $1.25 million. This strategic acquisition marks a significant expansion, diversification, and reinforcement of GENinCode's technological capabilities. The addition of Abcodia's advanced algorithm technology for the risk assessment of ovarian cancer (ROCA) enhances GENinCode's portfolio, particularly in the domain of early detection of ovarian cancer. Abcodia, also based in the UK, is recognized for its expertise in manufacturing biomarkers designed for the early identification of ovarian cancer. This acquisition underscores GENinCode's commitment to advancing its technology and expanding its offerings, positioning the company as a more comprehensive player in the field of genetic testing and diagnostics.

Major companies operating in the ovarian cancer diagnostics market report are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Bio-rad Laboratories Inc., Qiagen N.V., Natera Inc., The American Cancer Society, Myriad Genetics Inc., ArcherDX Inc., Invitae Corporation, Guardant Health, Luminex Corporation, NanoString Technologies Inc., Siemens Healthcare Private Limited, Menarini Silicon Biosystems S.p.A., Precipio Inc., Angle plc

North America was the largest region in the ovarian cancer diagnostic market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ovarian cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ovarian cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ovarian cancer diagnostic market includes revenues earned by entities by providing genetic testing, surgery, chemotherapy, target therapy, and hormone therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The ovarian cancer diagnostic market also includes sales of ultrasound machines, biopsy tools, genetic testing kits, immunohistochemistry (IHC) kits, and ovarian cancer biomarker panels. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ovarian Cancer Diagnostics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ovarian cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ovarian cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ovarian cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Product Type: Instruments; Kits; Reagents
  • 2) By Diagnosis Type: Biopsy; Blood Test; Imaging; Other Diagnosis Types
  • 3) By Cancer Type: Epithelial Tumor; Germ Cell Tumor; Stromal Cell Tumor; Other Cancer Types
  • 4) By End User: Cancer Diagnostic Centers; Hospital Laboratories; Research Institutes
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; AstraZeneca plc; Abbott Laboratories; GlaxoSmithKline plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ovarian Cancer Diagnostics Market Characteristics

3. Ovarian Cancer Diagnostics Market Trends And Strategies

4. Ovarian Cancer Diagnostics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Ovarian Cancer Diagnostics Market Size and Growth

  • 5.1. Global Ovarian Cancer Diagnostics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Ovarian Cancer Diagnostics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Ovarian Cancer Diagnostics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Ovarian Cancer Diagnostics Market Segmentation

  • 6.1. Global Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Instruments
  • Kits
  • Reagents
  • 6.2. Global Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Biopsy
  • Blood Test
  • Imaging
  • Other Diagnosis Types
  • 6.3. Global Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Epithelial Tumor
  • Germ Cell Tumor
  • Stromal Cell Tumor
  • Other Cancer Types
  • 6.4. Global Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Cancer Diagnostic Centers
  • Hospital Laboratories
  • Research Institutes

7. Ovarian Cancer Diagnostics Market Regional And Country Analysis

  • 7.1. Global Ovarian Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Ovarian Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Ovarian Cancer Diagnostics Market

  • 8.1. Asia-Pacific Ovarian Cancer Diagnostics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Ovarian Cancer Diagnostics Market

  • 9.1. China Ovarian Cancer Diagnostics Market Overview
  • 9.2. China Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Ovarian Cancer Diagnostics Market

  • 10.1. India Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Ovarian Cancer Diagnostics Market

  • 11.1. Japan Ovarian Cancer Diagnostics Market Overview
  • 11.2. Japan Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Ovarian Cancer Diagnostics Market

  • 12.1. Australia Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Ovarian Cancer Diagnostics Market

  • 13.1. Indonesia Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Ovarian Cancer Diagnostics Market

  • 14.1. South Korea Ovarian Cancer Diagnostics Market Overview
  • 14.2. South Korea Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Ovarian Cancer Diagnostics Market

  • 15.1. Western Europe Ovarian Cancer Diagnostics Market Overview
  • 15.2. Western Europe Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Ovarian Cancer Diagnostics Market

  • 16.1. UK Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Ovarian Cancer Diagnostics Market

  • 17.1. Germany Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Ovarian Cancer Diagnostics Market

  • 18.1. France Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Ovarian Cancer Diagnostics Market

  • 19.1. Italy Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Ovarian Cancer Diagnostics Market

  • 20.1. Spain Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Ovarian Cancer Diagnostics Market

  • 21.1. Eastern Europe Ovarian Cancer Diagnostics Market Overview
  • 21.2. Eastern Europe Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Ovarian Cancer Diagnostics Market

  • 22.1. Russia Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Ovarian Cancer Diagnostics Market

  • 23.1. North America Ovarian Cancer Diagnostics Market Overview
  • 23.2. North America Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Ovarian Cancer Diagnostics Market

  • 24.1. USA Ovarian Cancer Diagnostics Market Overview
  • 24.2. USA Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Ovarian Cancer Diagnostics Market

  • 25.1. Canada Ovarian Cancer Diagnostics Market Overview
  • 25.2. Canada Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Ovarian Cancer Diagnostics Market

  • 26.1. South America Ovarian Cancer Diagnostics Market Overview
  • 26.2. South America Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Ovarian Cancer Diagnostics Market

  • 27.1. Brazil Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Ovarian Cancer Diagnostics Market

  • 28.1. Middle East Ovarian Cancer Diagnostics Market Overview
  • 28.2. Middle East Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Ovarian Cancer Diagnostics Market

  • 29.1. Africa Ovarian Cancer Diagnostics Market Overview
  • 29.2. Africa Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Ovarian Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Ovarian Cancer Diagnostics Market Competitive Landscape
  • 30.2. Ovarian Cancer Diagnostics Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Thermo Fisher Scientific Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. AstraZeneca plc
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Abbott Laboratories
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. GlaxoSmithKline plc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Ovarian Cancer Diagnostics Market Other Major And Innovative Companies

  • 31.1. Eli Lilly and Company
  • 31.2. GE HealthCare Technologies Inc.
  • 31.3. Quest Diagnostics Incorporated
  • 31.4. Agilent Technologies Inc.
  • 31.5. Hologic Inc.
  • 31.6. Illumina Inc.
  • 31.7. PerkinElmer Inc.
  • 31.8. Sysmex Corporation
  • 31.9. Bio-rad Laboratories Inc.
  • 31.10. Qiagen N.V.
  • 31.11. Natera Inc.
  • 31.12. The American Cancer Society
  • 31.13. Myriad Genetics Inc.
  • 31.14. ArcherDX Inc.
  • 31.15. Invitae Corporation

32. Global Ovarian Cancer Diagnostics Market Competitive Benchmarking

33. Global Ovarian Cancer Diagnostics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Ovarian Cancer Diagnostics Market

35. Ovarian Cancer Diagnostics Market Future Outlook and Potential Analysis

  • 35.1 Ovarian Cancer Diagnostics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Ovarian Cancer Diagnostics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Ovarian Cancer Diagnostics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer